Oncternal Therapeutics
ONCT | NASDAQ
$0.53
-$0.16 (-23.63%)
At close: Dec 02, 2024, 04:00 PM ET
-23.63%
(1D)Rating
Key Statistics
Market Data
Market Cap $1.56M
1D Range
0.53 0.70
52W Range
0.53 10.61
Valuation (TTM)
PE -0.05
PB 0.17
EV/EBITDA 0.36
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $28.00
Cash Flow
FCF Yield -1708.8%
SBC Adj. FCF Yield -2146.0%
SBC Impact -25.6%
Margins
Gross Margin -3690.2%
Operating Margin -1664.0%
FCF Margin -1232.4%
Growth (CAGR)
Revenue 3Y | 5Y -26.1% |
0.0%
Dil EPS 3Y | 5Y -48.6% |
-54.3%
FCF 3Y | 5Y 12.1% |
-11.3%
Returns
ROA -107.5%
ROE 61.6%
ROIC -131.6%
Financial Health
Net Cash
$14.58M
Current Ratio 6.94
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating cancer treatments for diseases where current medical options are insufficient. Its clinical-stage portfoli...
Sector Healthcare
Industry Biotechnology
Employees 27
IPO Date Feb 3, 2004
Website www.oncternal.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove ONCT